Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
(Ezetimibe + obicetrapib) by NewAmsterdam Pharma Company for Heterozygous familial hypercholesterolemia (heFH): Likelihood of Approval
(Ezetimibe + obicetrapib) is under clinical development by NewAmsterdam Pharma Company and currently in Phase III for Heterozygous familial hypercholesterolemia...
Data Insights
(Ezetimibe + obicetrapib) by NewAmsterdam Pharma Company for Atherosclerosis: Likelihood of Approval
(Ezetimibe + obicetrapib) is under clinical development by NewAmsterdam Pharma Company and currently in Phase III for Atherosclerosis. According to...